Over a Decade of Award-Winning Excellence in Supporting Academic Research
- Established in 2013
- 275+ Research Agreements at 200+ Institutions in 30+ Countries
- 150+ Peer-Reviewed Publications, including 25+ Clinical Studies
- 2 Industry Awards
- Featured in Forbes
The ChromaDex External Research Program (CERP) is an essential component of ChromaDex’s Research and Development strategy. We value and encourage strong scientific rigor behind our products, and our relationships with academic institutions help make this happen. Through CERP, we provide ChromaDex material and technical expertise for exceptional preclinical and clinical, investigator-initiated research projects. Additionally, we fund select research studies supporting ChromaDex’s business needs. As a result, we have developed over 275 Material Transfer Agreements (MTAs) globally, totaling more than $4 million in material (based on market value). These efforts have resulted in more than 152 peer-reviewed publications, including 27 clinical studies.*
Why Should You Apply for CERP?
A History of Excellence
For over 20 years, ChromaDex has been an industry leader in analytical methods, reference standards, and proprietary ingredients. ChromaDex is the main owner and licensee of intellectual property (IP) related to nicotinamide riboside (NR). In collaboration with our strategic partners, ChromaDex manufactures both NR as an ingredient, Niagen®, and a finished dietary supplement product, Tru Niagen®, to the highest quality standards. We were honored with the “2019 Best of the Industry: Ingredient Supplier” award from Nutritional Outlook for our efforts to set the industry standard for excellence in commercial science and safety. We were also honored with the 2022 EU NutraIngredients Nutrition Research Award for “Developing the science behind NIAGEN®, ChromaDex’s Patented source of Nicotinamide Riboside, for cellular health”.
High Quality Safety Tested Material and Regulatory Acceptance
Our NR has been successfully notified to the FDA as both a New Dietary Ingredient (NDI) and a Generally Recognized as Safe (GRAS) ingredient, both acknowledgments of its safety and acceptance for dietary supplement and food applications in the US. Our product has also received a positive opinion from the European Food Safety Authority and was approved as a novel food ingredient by the European Commission. Elsewhere, our product has been approved as a natural health product by Health Canada and approved by the Therapeutic Goods Administration of Australia as a complementary medicine. We are the only NR-Cl product that has obtained any of these safety reviews and approvals. Our ingredient is also analyzed in an ISO accredited laboratory.
Our Material is Trusted
When it comes to clinical research, independent investigators overwhelmingly chose ChromaDex’s Niagen®. Approximately 70% of NR studies registered on clinicaltrials.gov are using or have used our materials.
We Build Relationships
One of the goals of CERP is to build community and provide support to external investigators. From the application process to MTA development to publications and beyond, we provide CERP Investigators (CERPIs) with protocol recommendations, letters of support, manuscript peer-review, intellectual property insights, and more. We want CERPIs to improve their likelihood of success while still maintaining independence and research integrity.
As you determine the source of NR that you will use for your future studies, please keep the following in mind:
- Some forms of NR-CI are unstable. ChromaDex’s crystalline form is highly stable as a powder. Other providers may sell a highly unstable, amorphous form that quickly gelatinizes when exposed to air, resulting in degradation.
- Isomeric purity. Our Niagen® is evaluated for the beta-NR conformation to ensure it is the bioactive form. If the NR-Cl is a mixture of alpha- and beta-NR, the efficacy may be reduced, and little is known if the alpha-NR conformation would inhibit the NAD+ biochemical pathway.
- The successful review of Niagen® and approval by regulators worldwide is a direct reflection of the strong science, safety, quality, and consistency behind it. We possess an intimate understanding of the manufacturing process and composition of the final ingredient material. For third-party sourced NR-Cl, there is little known about the potential contaminants (by-products, solvents, impurities), which could impact study results and reproducibility.
Examples of Recent Peer Reviewed CERP Publications
Investigator Initiated Preclinical Research
- Stock et al. (2023) Boosting NAD ameliorates hematopoietic impairment linked to short telomeres in vivo. GeroScience, 1–16.
- Pang et al. (2023) Nicotinamide Adenine Dinucleotide Precursor Suppresses Hepatocellular Cancer Progression in Mice. Nutrients, 15, 1447.
- Pezzotta et al. (2022) Low Nephron Number Induced by Maternal Protein Restriction Is Prevented by Nicotinamide Riboside Supplementation Depending on Sirtuin 3 Activation. Cells, 11, 3316.
- Sun et al. (2021) Nicotinamide riboside attenuates age-associated metabolic and functional changes in hematopoietic stem cells. Nature Communications, 12, 2665.
- Seldeen et al. (2021) Short-term nicotinamide riboside treatment improves muscle quality and function in mice and increases cellular energetics and differentiating capacity of myogenic progenitors. Nutrition, 87, 111189.
Investigator Initiated Clinical Research
- Brakedal et al. (2022) The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metabolism, 34, 396-407.e6.
- Vreones et al. (2022) Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin. Aging Cell, 22, e13754.
- Lapatto et al. (2023) Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study. Science Advances, 9, eadd5163.
- Wu et al. (2022) Boosting NAD+ blunts toll-like receptor-4 induced type-I interferon in control and systemic lupus erythematosus monocytes. Journal of Clinical Investigation, 132, e139828.
- Wang et al. (2022) Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction. JACC: Basic to Translational Science, 7, 1183–96.
ChromaDex Sponsored Peer-Reviewed Research
- Trammell et al. “Nicotinamide riboside is uniquely and orally bioavailable in mice and humans.” Nature Communications 7 (2016): 12948.
- Conze et al. “Safety assessment of nicotinamide riboside, a form of vitamin B3.” Human & Experimental Toxicology 35.11 (2016): 1149-1160.
- Conze et al. “Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults.” Scientific Reports 9.1 (2019): 1-13.
- Hayat and Migaud. “Nicotinamide riboside–amino acid conjugates that are stable to purine nucleoside phosphorylase.” Organic & Biomolecular Chemistry 18.15 (2020): 2877-2885.
We are currently prioritizing partnerships with academic researchers looking to use nicotinamide riboside and other ChromaDex materials to advance knowledge in one or more of the following age related research areas**:
- Exercise and muscle health
- Fatigue & energy benefits
- Cognition and brain health
- Heart health
- Liver health
- Immune and inflammation health
- Companion Animal health
- Reproductive health
If you are interested in becoming a CERP Investigator, using ChromaDex materials for your research, please download and complete the appropriate application above. As our program is highly selective, we recommend that you finalize your protocol details and obtain the required ethical approval(s) before submitting your CERP application. An esteemed group of internal multi-disciplinary scientists will evaluate and score your application and supplementary materials. Typically, we provide a response or request for additional information within 30 days of receiving the application. If selected for the program, we will then develop a Material Transfer Agreement (MTA) to issue the material(s) and provide technical expertise.
For more information and application submission, please email [email protected].
- CERPI Newsletter Vol 4, Issue 3 Sep 2023
- CERPI Newsletter Vol 4, Issue 2 Jun 2023
- CERPI Newsletter Vol 4, Issue 1 Mar 2023
- CERPI Newsletter Vol 3, Issue 4 Dec 2022
- CERPI Newsletter Vol 3, Issue 3 Sep 2022
- CERPI Newsletter Vol 3, Issue 2 Jun 2022
- CERPI Newsletter Vol 3, Issue 1 Mar 2022
- CERPI Newsletter Vol 2, Issue 4 Dec 2021
- CERPI Newsletter Vol 2, Issue 3 Sep 2021
- CERPI Newsletter Vol 2, Issue 2 Jun 2021
- CERPI Newsletter Vol 2, Issue 1 Jan 2021
*As of June 13, 2023
** These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.